moneyheap
ARE · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Alexandria Real Estate Equities, Inc. (ARE) stock moving?
The most visible news is a cluster of analyst target cuts between Oct 28 and Nov 3: Cantor Fitzgerald and Citigroup each moved to $42, BNP Paribas to $37 with Underperform, and RBC to $47 with Sector Perform. The average of these four targets is about $42, and all four ratings are Neutral, Sector Perform or Underperform, so the sell side is not positive. Around the same period, ARE fell from a $43.40 close on Oct 26 to a $38.34 intraday low on Oct 28, on volume of 5.6M, and KKR's $475M joint venture in Campus Point was announced the same day. The stock then rebounded: on Nov 4 it closed at $46.00, up about 8.8% from $42.28 on heavy volume of 4.7M, and it has since traded between $44.70 and $45.88. No news item in the set explains the Nov 4 move, and the Q3 2026 supplement exists but its figures are not in the excerpt. Volume has faded to 1.29M on Nov 10, and the close of $44.70 sits above three of the four targets but below RBC's $47. Overall the picture is mixed: the KKR capital deal and the rebound support the stock, while the target cuts and low ratings cap it.
News behind the analysis
- RBC Capital Maintains Sector Perform on Alexandria Real Estate, Lowers Price Target to $47RBC kept its Sector Perform rating and cut its price target to $47. The move follows a lower target from RBC.
- RBC Cuts Price Target on Alexandria Real Estate Equities to $47RBC lowered its price target from $51 to $47 while maintaining a Sector Perform rating.
- Citigroup Maintains Neutral Rating on Alexandria Real Estate Equities and Lowers Price TargetCitigroup kept its Neutral rating and cut its price target from $50 to $42.
- Citigroup Maintains Neutral on Alexandria Real Estate, Lowers Price Target to $42Citigroup reiterated Neutral and lowered its price target to $42, the same change reported by other outlets.
- Alexandria Real Estate Equities Executives Co-Moderate Panel on MAP-D InitiativeJoel S. Marcus and Dr. Lynne Zydowsky co-moderated an FNIH panel on the MAP-D initiative. The item is an event appearance with no financial figures.
- KKR Invests $475 Million in Alexandria Real Estate Equities' Campus PointKKR entered a $475 million joint venture investment in Campus Point, a nearly 2 million-square-foot life science Megacampus in San Diego. This is the most significant capital deal in the set.
- Cantor Fitzgerald Maintains Neutral on Alexandria Real Estate, Lowers Price Target to $42Cantor Fitzgerald kept its Neutral rating and lowered its price target to $42.
- BNP Paribas Maintains Underperform on Alexandria Real Estate, Lowers Price Target to $37BNP Paribas kept its Underperform rating and lowered its price target to $37, the lowest target among the analysts covered here.
- 8-K (results of operations, exhibits)Filed the third quarter 2026 earnings supplement (EX-99.1) covering the period ended September 30, 2026. The excerpt provided shows only the table of contents, so the reported figures are not visible here.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities is a real estate investment trust (REIT) based in Pasadena, California. It owns, develops and leases lab and office campuses for life science, agtech and technology tenants in innovation clusters such as Greater Boston, San Francisco, San Diego, Seattle, Maryland, Research Triangle and New York.
How it makes money
Most of its income comes from rent on long-term leases of lab and office space. Many of these are triple-net leases, meaning tenants also pay back operating costs such as taxes, insurance and upkeep. Its tenants include pharmaceutical and biotech companies, research institutions and tech firms. It earns smaller amounts from selling properties and from gains on venture investments in life science companies (roughly $65M expected for 2026). Quarterly revenue in Q3 2026 was about $670M, down about 11% from a year earlier. Occupancy has fallen to about 87% because too much lab space has been built and demand is softer. In 2026 the company also booked large impairment charges, which are write-downs in the value of its properties.
What usually moves ARE
- Biotech funding and life science leasing demand
- Lab space oversupply and occupancy rates
- Interest rates and REIT financing costs
- Property impairments and asset sales
- Development pipeline costs and leverage